Breakthrough personalized mRNA vaccine cuts melanoma recurrence risk by 50% when combined with Keytruda, Moderna CEO reveals ...
Five-year data from the KEYNOTE–942 trial show that the personalized mRNA cancer vaccine intismeran autogene, combined with ...
Two and a half years after Sanofi unveiled to investors a revamped strategy to create an mRNA seasonal flu vaccine, Fierce Biotech has learned that the French pharma has put this pipeline on ice.
As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans ...
mRNA Synthesis and Manufacturing Market to Witness a Leap by Leaching CAGR of ~6% By The End Of 2030
Global mRNA Synthesis and Manufacturing Market OverviewThe global mRNA synthesis and manufacturing market is projected to grow at a compound annual growth rate of approximately 6% during the forecast ...
Five years ago, a group of high-risk skin cancer patients received a bespoke vaccine. The data is finally in, and the results ...
Despite Sanofi CEO Paul Hudson’s confidence in vaccines, the French pharma has cut at least one mRNA flu shot program.
Covid vaccines may come with a tantalizing benefit that has nothing to do with the virus they’re designed to protect against: boosting the immune system to better fight tumors during cancer treatment.
Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.
In this episode of Denatured, Jennifer C. Smith-Parker speaks to Erik Digman Wiklund, CEO of Circio and Jacob Becraft, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results